| Name | Title | Contact Details |
|---|
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body`s natural defense system.
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs
PreciThera, Inc. is a biotechnology company committed to the development of therapies for rare bone diseases using the combined application of computational technology and a deep understanding of disease pathology.
CardioVascular BioTherapeutics, Inc. is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.